Company: NCNA
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0000950170-25-042709
Chunk: 219

Company: NuCana plc
Filing Date: 2025-03-20
Form: 20-F
Item: Item 7
Chunk 219
---
                                                               275,625      *        
  All of our executive officers and directors, as a group (10 persons)           13,326,652               

* Indicates beneficial ownership of less than one percent of our ordinary shares.

(1)

Number of shares owned as shown both in this table and the accompanying footnotes and percentage ownership is based on 142,037,199 ordinary shares outstanding on December 31, 2024 after giving effect to the exercise of all outstanding vested options to purchase our ordinary shares held by our executive officers and directors.

(2)

Consists of (a) 1,000,000 ordinary shares, (b) 265,026 ordinary shares in the form of ADSs, and (c) options to purchase 5,098,977 ordinary shares that are or will be immediately exercisable within 60 days of December 31, 2024.

(3)

Consists of (a) 263,838 ordinary shares and (b) options to purchase 1,474,612 ordinary shares that are immediately exercisable within 60 days of December 31, 2024. Mr. Munoz was our Chief Financial Officer until February 2025.

(4)

Consists of (a) 540 ordinary shares in the form of ADSs, (b) 3,333,333 ADSs held by Abingworth Bioventures VII LP, or Abingworth VII, and (c) options to purchase 96,189 ordinary shares that are or will be immediately exercisable within 60 days of December 31, 2024. Abingworth VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth VII. Abingworth LLP holds the reported securities indirectly through Abingworth VII. Dr. Muralidhar, a member of our board of directors, is a partner and investment committee member of Abingworth LLP and disclaims beneficial ownership of the ADSs held by Abingworth VII.

(5)

Consists of (a) 16 ordinary shares, (b) 33,214 ordinary shares in the form of ADSs and (c) 197,672 options to purchase ordinary shares that are or will be immediately exercisable within 60 days of December 31, 2024.

(6)

Consists of (a) 13 ordinary